Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

PMID:
29305520
2.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, Peretz T, Lotem M, Gross G.

Clin Exp Immunol. 2015 Nov;182(2):220-9. doi: 10.1111/cei.12688. Epub 2015 Aug 28.

3.

A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.

Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, K├Ânig R, Bernhard H, Machlenkin A, Boutros M, Beckhove P.

EMBO Mol Med. 2015 Apr;7(4):450-63. doi: 10.15252/emmm.201404414.

4.

Human T cell crosstalk is induced by tumor membrane transfer.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, Engelstein R, Peretz T, Machlenkin A, Lotem M.

PLoS One. 2015 Feb 11;10(2):e0118244. doi: 10.1371/journal.pone.0118244. eCollection 2015.

5.

Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2013 Jun 1;190(11):5856-65. doi: 10.4049/jimmunol.1202879. Epub 2013 Apr 26.

6.

Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.

Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, Yefenof E, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2012 Jan 15;188(2):632-40. doi: 10.4049/jimmunol.1101429. Epub 2011 Dec 7.

7.

Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells.

Volovitz I, Marmor Y, Azulay M, Machlenkin A, Goldberger O, Mor F, Slavin S, Ram Z, Cohen IR, Eisenbach L.

J Immunol. 2011 Nov 15;187(10):5452-62. doi: 10.4049/jimmunol.1003946. Epub 2011 Oct 12.

8.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
9.

Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, Peretz T, Lotem M.

Cell Immunol. 2010;266(1):98-103. doi: 10.1016/j.cellimm.2010.09.003. Epub 2010 Sep 18.

10.

T-cell seeding: neonatal transfer of anti-myelin basic protein T-cell lines renders Fischer rats susceptible later in life to the active induction of experimental autoimmune encephalitis.

Volovitz I, Mor F, Machlenkin A, Goldberger O, Marmor Y, Eisenbach L, Cohen IR.

Immunology. 2009 Sep;128(1):92-102. doi: 10.1111/j.1365-2567.2009.03074.x. Erratum in: Immunology. 2009 Nov;128(3):459. Machlenkin, Athur [corrected to Machlenkin, Arthur]; Cohen, Irun [corrected to Cohen, Irun R].

11.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

12.

Exuberated numbers of tumor-specific T cells result in tumor escape.

Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L.

Cancer Res. 2008 May 1;68(9):3450-7. doi: 10.1158/0008-5472.CAN-07-5006.

13.

Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.

Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M.

Cancer Res. 2008 Mar 15;68(6):2006-13. doi: 10.1158/0008-5472.CAN-07-3119.

14.

'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, Eisenbach L.

Br J Cancer. 2007 Dec 17;97(12):1655-63. Epub 2007 Dec 11.

15.

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.

Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L.

Cancer Immunol Immunother. 2007 Feb;56(2):217-26. Epub 2006 Jun 1.

PMID:
16738849
16.

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.

17.

Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.

Clin Cancer Res. 2005 Jul 1;11(13):4955-61.

18.

MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.

Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L.

Br J Cancer. 2004 Jul 19;91(2):398-407.

19.

In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.

Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.

Cancer Gene Ther. 2004 Mar;11(3):237-48.

PMID:
14739939
20.

1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.

Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R.

Cancer Res. 1999 Feb 15;59(4):862-7.

Supplemental Content

Loading ...
Support Center